Urinary Tract Infection Treatment Market Size, Share, Competitive Landscape and Trend Analysis Report by Drug Type, Application, Distribution Channel, and Region: Global Opportunity Analysis and Industry Forecast, 2024-2033

The urinary tract infection treatment market was valued at $9,870.00 million in 2023 and is estimated to reach $17,100.41 million by 2033, exhibiting a CAGR of 5.7% from 2024 to 2033.

Market Introduction and Definition

Urinary tract infection (UTI) treatment involves medical strategies aimed at eradicating the infection, alleviating symptoms, and preventing recurrence. UTIs are commonly caused by bacteria, predominantly Escherichia coli, entering the urinary tract, affecting the bladder (cystitis), urethra (urethritis), or kidneys (pyelonephritis). The treatment approach varies based on the infection's severity, location, and patient-specific factors such as age, sex, and underlying health conditions.

Key Takeaways

• The urinary tract infection treatment market study covers 20 countries. The research includes a segment analysis of each country in terms of value ($million) for the projected period from 2024 to 2033.
• More than 1,500 product literatures, industry releases, annual reports, and other such documents of major energy storage system industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
• The study integrates high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach intends to provide a balanced view of global markets and assist stakeholders in making informed decisions in order to achieve their most ambitious growth objectives.

Industry Trends

• In August 2021, Bayer AG, a multinational pharmaceutical and biotechnology company based in Germany, announced its acquisition of Vividion Therapeutics, a U.S.-based biopharmaceutical firm. Vividion uses innovative discovery technologies to target traditionally undruggable high-value areas with precision therapeutics.
• In November 2020, Allergan revealed that the FDA had accepted their Supplemental New Drug Indication for Avycaz. This new indication covers the treatment of patients dealing with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).
• In October 2020, Bayer AG acquired Asklepios BioPharmaceutical, Inc., a gene therapy firm. Asklepios BioPharmaceutical, Inc.'s portfolio features investigational candidates in both pre-clinical and clinical stages aimed at treating central nervous system, neuromuscular, cardiovascular, and metabolic diseases.
• In January 2019, AstraZeneca, a global biopharmaceutical company driven by science, completed its acquisition of Shire, another biopharmaceutical firm. This merger brought together Takeda Pharmaceutical Company Limited, a global biopharmaceutical company, and Shire's complementary expertise in gastrointestinal and neuroscience fields. This integration aims to establish leading positions in rare diseases, enhancing Takeda's already strong presence in oncology and its dedicated efforts in vaccines.

Key Market Dynamics

UTIs are among the most common infections globally, affecting millions of people each year. The high incidence rate, particularly among women, elderly individuals, and people with certain medical conditions, drives the demand for effective treatments. UTIs affect millions of people each year, with women being particularly susceptible. Studies show that about 50-60% of women will experience at least one UTI in their lifetime. These are the major factors driving the UTI treatment market growth.

The urinary tract infection (UTI) treatment market faces significant challenges due to the increasing prevalence of antibiotic-resistant bacteria, such as E. coli. This resistance to antibiotics poses a major threat to effective UTI treatment. In the U.S., at least 2.8 million people get an antibiotic-resistant infection each year, and more than 35,000 people die as a result. Antibiotic resistance is one of the biggest threats to global health, food security, and development. It can affect anyone, of any age, in any country. The WHO estimates that antibiotic resistance could cause 10 million deaths annually by 2050, if no action is taken.

Advances in diagnostic techniques, such as molecular diagnostics and point-of-care testing, enable faster and more accurate diagnosis of UTIs. Moreover, the development of novel therapeutic agents, including antibiotics and vaccines, enhances treatment outcomes and reduces the risk of antibiotic resistance. These factors are projected to create several growth opportunities in the market during the forecast period.

Public Policies of Urinary Tract Infection Treatment Market

• Antibiotic Stewardship Programs: Government health agencies often implement antibiotic stewardship programs aimed at promoting the judicious use of antibiotics to combat antibiotic resistance, a growing concern in UTI treatment. These programs provide guidelines for healthcare providers to optimize antibiotic prescribing practices. According to the Centers for Disease Control and Prevention (CDC), at least 30% of antibiotics prescribed in outpatient settings in the U.S. are unnecessary, contributing to antibiotic resistance.
• Guidelines for UTI Diagnosis and Treatment: Governments often develop and disseminate guidelines for the diagnosis and treatment of UTIs based on the latest scientific evidence. These guidelines help standardize care and improve patient outcomes. The National Institute for Health and Care Excellence (NICE) in the UK provides clinical guidelines for the management of UTIs, including recommendations on appropriate antibiotic use and when to consider non-antibiotic treatments.

Market Segmentation

The urinary tract infection treatment market is segmented into drug type, application, distribution channel, and region. On the basis of drug type, the market is divided into penicillin & combinations, quinolones, cephalosporin, aminoglycoside antibiotics, sulphonamides, azoles & amphotericin b, tetracycline (doxycycline), nitrofurans (nitrofurantoin), and others. On the basis of application, the market is classified into complicated urinary tract infection and uncomplicated urinary tract infection. On the basis of distribution channel, the market is divided into hospital pharmacies, gynecology & urology clinics, drug stores, retail pharmacies, and online drug stores. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Country Market Outlook

UTIs are one of the most common bacterial infections in the U.S., affecting millions of individuals annually. According to the Centers for Disease Control and Prevention (CDC), there are approximately 8.1 million UTI-related visits to healthcare providers each year. The aging population is more susceptible to UTIs due to weakened immune systems and other age-related factors. The U.S. Census Bureau reports that the proportion of the population aged 65 and older is steadily increasing and is expected to rise further. The emergence of antibiotic-resistant UTI strains has become a significant concern. According to the CDC, over 2.8 million antibiotic-resistant infections occur in the U.S. each year, leading to more than 35,000 deaths. This drives the need for alternative treatments and boosts R&D efforts in the UTI treatment market.

• In October 2021, Spero Therapeutics Inc. filed a new drug application (NDA) with the U.S. Food and Drug Administration (FDA), aiming to obtain approval for tebipenem HBr tablets. These tablets are intended for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms.
• In January 2020, Merck received approval from the U.S. FDA for its drug DIFICID (fidaxomicin), expanding its usage to include treating Clostridioides difficile bacteria in both pediatric populations and older children.

Competitive Landscape

The major players operating in the urinary tract infection treatment market include Pfizer, Bayer AG, Almirall SA, GlaxoSmithKline Pharmaceuticals Ltd., Merck & Co. Inc., Bristol-Myers, Squibb Shionogi & Co. Ltd, Cipla Inc, Novartis AG, Dr. Reddy’s Laboratories Ltd., and others.

Recent Key Strategies and Developments

• In September 2021, BDR Pharma, a prominent generic pharmaceutical company in India, introduced biapenem for the treatment of patients suffering from intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.
• On November 16, 2020, Pfizer Inc. (NYSE: PFE) announced that it had completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc.

Key Sources Referred

1. National Health Service (NHS)
2. European Association of Urology (EAU)
3. American Journal of Medicine
4. World Health Organization (WHO)
5. National Institute on Aging
6. Centers for Disease Control and Prevention (CDC)

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the urinary tract infection treatment market segments, current trends, estimations, and dynamics of the urinary tract infection treatment market analysis from 2023 to 2033 to identify the prevailing urinary tract infection treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the urinary tract infection treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global urinary tract infection treatment market statistics.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

Apart from the above-mentioned points, the report includes the analysis of the regional as well as global urinary tract infection treatment market trends, key players, market segments, application areas, and market growth strategies.

1. Research Methodology

1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.5. Market size estimation

1.5.1. Top-down approach
1.5.2. Bottom-up approach

2. Report Scope

2.1. Market definition
2.2. Key objectives of the study
2.3. Market segmentation

3. Executive Summary
4. Market Overview

4.1. Introduction
4.2. Growth impact forces

4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities

4.3. Market value chain analysis

4.3.1. List of raw material suppliers
4.3.2. List of manufacturers 
4.3.3. List of distributors

4.4. Innovation & sustainability matrices

4.4.1. Technology matrix
4.4.2. Regulatory matrix

4.5. Porter’s five forces analysis

4.5.1. Bargaining power of suppliers
4.5.2. Bargaining power of consumers
4.5.3. Threat of substitutes
4.5.4. Threat of new entrants
4.5.5. Competitive Rivalry Intensity

4.6. PESTLE analysis

4.6.1. Political
4.6.2. Economical
4.6.3. Social
4.6.4. Technological
4.6.5. Legal
4.6.6. Environmental

4.7. Impact of COVID-19 on Urinary Tract Infection Treatment Market 

4.7.1. Pre-covid market scenario
4.7.2. Post-covid market scenario

5. Urinary Tract Infection Treatment Market Analysis, by Drug Type

5.1. Overview
5.2. Penicillin & Combinations

5.2.1. Definition, key trends, growth factors, and opportunities
5.2.2. Market size analysis, by region, 2022-2032
5.2.3. Market share analysis, by country, 2022-2032

5.3. Quinolones

5.3.1. Definition, key trends, growth factors, and opportunities
5.3.2. Market size analysis, by region, 2022-2032
5.3.3. Market share analysis, by country, 2022-2032

5.4. Cephalosporin

5.4.1. Definition, key trends, growth factors, and opportunities
5.4.2. Market size analysis, by region, 2022-2032
5.4.3. Market share analysis, by country, 2022-2032

5.5. Aminoglycoside Antibiotics

5.5.1. Definition, key trends, growth factors, and opportunities
5.5.2. Market size analysis, by region, 2022-2032
5.5.3. Market share analysis, by country, 2022-2032

5.6. Sulphonamides

5.6.1. Definition, key trends, growth factors, and opportunities
5.6.2. Market size analysis, by region, 2022-2032
5.6.3. Market share analysis, by country, 2022-2032

5.7. Azoles & Amphotericin B

5.7.1. Definition, key trends, growth factors, and opportunities
5.7.2. Market size analysis, by region, 2022-2032
5.7.3. Market share analysis, by country, 2022-2032

5.8. Tetracycline (Doxycycline)

5.8.1. Definition, key trends, growth factors, and opportunities
5.8.2. Market size analysis, by region, 2022-2032
5.8.3. Market share analysis, by country, 2022-2032

5.9. Nitrofurans (Nitrofurantoin)

5.9.1. Definition, key trends, growth factors, and opportunities
5.9.2. Market size analysis, by region, 2022-2032
5.9.3. Market share analysis, by country, 2022-2032

5.10. Others

5.10.1. Definition, key trends, growth factors, and opportunities
5.10.2. Market size analysis, by region, 2022-2032
5.10.3. Market share analysis, by country, 2022-2032

5.11. Research Dive Exclusive Insights

5.11.1. Market attractiveness
5.11.2. Competition heatmap

6. Urinary Tract Infection Treatment Market Analysis, by Application

6.1. Overview
6.2. Complicated Urinary Tract Infection

6.2.1. Definition, key trends, growth factors, and opportunities
6.2.2. Market size analysis, by region, 2022-2032
6.2.3. Market share analysis, by country, 2022-2032

6.3. Uncomplicated Urinary Tract Infection

6.3.1. Definition, key trends, growth factors, and opportunities
6.3.2. Market size analysis, by region, 2022-2032
6.3.3. Market share analysis, by country, 2022-2032

6.4. Research Dive Exclusive Insights

6.4.1. Market attractiveness
6.4.2. Competition heatmap

7. Urinary Tract Infection Treatment Market Analysis, by Distribution Channel

7.1. Overview
7.2. Hospital Pharmacies

7.2.1. Definition, key trends, growth factors, and opportunities
7.2.2. Market size analysis, by region, 2022-2032
7.2.3. Market share analysis, by country, 2022-2032

7.3. Gynecology & Urology Clinics

7.3.1. Definition, key trends, growth factors, and opportunities
7.3.2. Market size analysis, by region, 2022-2032
7.3.3. Market share analysis, by country, 2022-2032

7.4. Drug Stores

7.4.1. Definition, key trends, growth factors, and opportunities
7.4.2. Market size analysis, by region, 2022-2032
7.4.3. Market share analysis, by country, 2022-2032

7.5. Retail Pharmacies

7.5.1. Definition, key trends, growth factors, and opportunities
7.5.2. Market size analysis, by region, 2022-2032
7.5.3. Market share analysis, by country, 2022-2032

7.6. Online Drug Stores

7.6.1. Definition, key trends, growth factors, and opportunities
7.6.2. Market size analysis, by region, 2022-2032
7.6.3. Market share analysis, by country, 2022-2032

7.7. Research Dive Exclusive Insights

7.7.1. Market attractiveness
7.7.2. Competition heatmap

8. Urinary Tract Infection Treatment Market, by Region

8.1. North America

8.1.1. U.S.

8.1.1.1. Market size analysis, by Drug Type, 2022-2032
8.1.1.2. Market size analysis, by Application, 2022-2032
8.1.1.3. Market size analysis, by Distribution Channel, 2022-2032

8.1.2. Canada

8.1.2.1. Market size analysis, by Drug Type, 2022-2032
8.1.2.2. Market size analysis, by Application, 2022-2032
8.1.2.3. Market size analysis, by Distribution Channel, 2022-2032

8.1.3. Mexico

8.1.3.1. Market size analysis, by Drug Type, 2022-2032
8.1.3.2. Market size analysis, by Application, 2022-2032
8.1.3.3. Market size analysis, by Distribution Channel, 2022-2032

8.1.4. Research Dive Exclusive Insights

8.1.4.1. Market attractiveness
8.1.4.2. Competition heatmap

8.2. Europe

8.2.1. Germany 

8.2.1.1. Market size analysis, by Drug Type, 2022-2032
8.2.1.2. Market size analysis, by Application, 2022-2032
8.2.1.3. Market size analysis, by Distribution Channel, 2022-2032

8.2.2. UK

8.2.2.1. Market size analysis, by Drug Type, 2022-2032
8.2.2.2. Market size analysis, by Application, 2022-2032
8.2.2.3. Market size analysis, by Distribution Channel, 2022-2032

8.2.3. France

8.2.3.1. Market size analysis, by Drug Type, 2022-2032
8.2.3.2. Market size analysis, by Application, 2022-2032
8.2.3.3. Market size analysis, by Distribution Channel, 2022-2032

8.2.4. Spain

8.2.4.1. Market size analysis, by Drug Type, 2022-2032
8.2.4.2. Market size analysis, by Application, 2022-2032
8.2.4.3. Market size analysis, by Distribution Channel, 2022-2032

8.2.5. Italy

8.2.5.1. Market size analysis, by Drug Type, 2022-2032
8.2.5.2. Market size analysis, by Application, 2022-2032
8.2.5.3. Market size analysis, by Distribution Channel, 2022-2032

8.2.6. Rest of Europe

8.2.6.1. Market size analysis, by Drug Type, 2022-2032
8.2.6.2. Market size analysis, by Application, 2022-2032
8.2.6.3. Market size analysis, by Distribution Channel, 2022-2032

8.2.7. Research Dive Exclusive Insights

8.2.7.1. Market attractiveness
8.2.7.2. Competition heatmap

8.3. Asia-Pacific

8.3.1. China

8.3.1.1. Market size analysis, by Drug Type, 2022-2032
8.3.1.2. Market size analysis, by Application, 2022-2032
8.3.1.3. Market size analysis, by Distribution Channel, 2022-2032

8.3.2. Japan 

8.3.2.1. Market size analysis, by Drug Type, 2022-2032
8.3.2.2. Market size analysis, by Application, 2022-2032
8.3.2.3. Market size analysis, by Distribution Channel, 2022-2032

8.3.3. India

8.3.3.1. Market size analysis, by Drug Type, 2022-2032
8.3.3.2. Market size analysis, by Application, 2022-2032
8.3.3.3. Market size analysis, by Distribution Channel, 2022-2032

8.3.4. Australia

8.3.4.1. Market size analysis, by Drug Type, 2022-2032
8.3.4.2. Market size analysis, by Application, 2022-2032
8.3.4.3. Market size analysis, by Distribution Channel, 2022-2032

8.3.5. South Korea

8.3.5.1. Market size analysis, by Drug Type, 2022-2032
8.3.5.2. Market size analysis, by Application, 2022-2032
8.3.5.3. Market size analysis, by Distribution Channel, 2022-2032

8.3.6. Rest of Asia-Pacific

8.3.6.1. Market size analysis, by Drug Type, 2022-2032
8.3.6.2. Market size analysis, by Application, 2022-2032
8.3.6.3. Market size analysis, by Distribution Channel, 2022-2032

8.3.7. Research Dive Exclusive Insights

8.3.7.1. Market attractiveness
8.3.7.2. Competition heatmap

8.4. LAMEA

8.4.1. Brazil

8.4.1.1. Market size analysis, by Drug Type, 2022-2032
8.4.1.2. Market size analysis, by Application, 2022-2032
8.4.1.3. Market size analysis, by Distribution Channel, 2022-2032

8.4.2. UAE

8.4.2.1. Market size analysis, by Drug Type, 2022-2032
8.4.2.2. Market size analysis, by Application, 2022-2032
8.4.2.3. Market size analysis, by Distribution Channel, 2022-2032

8.4.3. Saudi Arabia

8.4.3.1. Market size analysis, by Drug Type, 2022-2032
8.4.3.2. Market size analysis, by Application, 2022-2032
8.4.3.3. Market size analysis, by Distribution Channel, 2022-2032

8.4.4. South Africa

8.4.4.1. Market size analysis, by Drug Type, 2022-2032
8.4.4.2. Market size analysis, by Application, 2022-2032
8.4.4.3. Market size analysis, by Distribution Channel, 2022-2032

8.4.5. Rest of LAMEA

8.4.5.1. Market size analysis, by Drug Type, 2022-2032
8.4.5.2. Market size analysis, by Application, 2022-2032
8.4.5.3. Market size analysis, by Distribution Channel, 2022-2032

8.4.6. Research Dive Exclusive Insights

8.4.6.1. Market attractiveness
8.4.6.2. Competition heatmap

9. Competitive Landscape

9.1. Top winning strategies, 2022

9.1.1. By strategy
9.1.2. By year

9.2. Strategic overview
9.3. Market share analysis, 2022

10. Company Profiles

10.1. Pfizer

10.1.1. Overview
10.1.2. Business segments
10.1.3. Product portfolio
10.1.4. Financial performance
10.1.5. Recent developments
10.1.6. SWOT analysis

10.2. Bayer AG

10.2.1. Overview
10.2.2. Business segments
10.2.3. Product portfolio
10.2.4. Financial performance
10.2.5. Recent developments
10.2.6. SWOT analysis

10.3. Almirall SA

10.3.1. Overview
10.3.2. Business segments
10.3.3. Product portfolio
10.3.4. Financial performance
10.3.5. Recent developments
10.3.6. SWOT analysis

10.4. GlaxoSmithKline Pharmaceuticals Ltd.

10.4.1. Overview
10.4.2. Business segments
10.4.3. Product portfolio
10.4.4. Financial performance
10.4.5. Recent developments
10.4.6. SWOT analysis

10.5. Merck & Co. Inc.

10.5.1. Overview
10.5.2. Business segments
10.5.3. Product portfolio
10.5.4. Financial performance
10.5.5. Recent developments
10.5.6. SWOT analysis

10.6. Bristol-Myers

10.6.1. Overview
10.6.2. Business segments
10.6.3. Product portfolio
10.6.4. Financial performance
10.6.5. Recent developments
10.6.6. SWOT analysis

10.7. Squibb Shionogi & Co. Ltd

10.7.1. Overview
10.7.2. Business segments
10.7.3. Product portfolio
10.7.4. Financial performance
10.7.5. Recent developments
10.7.6. SWOT analysis

10.8. Cipla Inc

10.8.1. Overview
10.8.2. Business segments
10.8.3. Product portfolio
10.8.4. Financial performance
10.8.5. Recent developments
10.8.6. SWOT analysis

10.9. Novartis AG

10.9.1. Overview
10.9.2. Business segments
10.9.3. Product portfolio
10.9.4. Financial performance
10.9.5. Recent developments
10.9.6. SWOT analysis

10.10. Dr. Reddys Laboratories Ltd.

10.10.1. Overview
10.10.2. Business segments
10.10.3. Product portfolio
10.10.4. Financial performance
10.10.5. Recent developments
10.10.6. SWOT analysis

* Taxes/Fees, If applicable will be added during checkout. All prices in USD.